Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy | Zendy

Marek Cmero | Zendy; Natalie J. Kurganovs | Zendy; Ryan Stuchbery | Zendy; Patrick J. McCoy | Zendy; Corrina Grima | Zendy; Anne Ngyuen | Zendy; Ken Chow | Zendy; Stefano Mangiola | Zendy; Geoff Macintyre | Zendy; Nicholas Howard | Zendy; Michael Kerger | Zendy; Philip Dundee | Zendy; Paul Ruljancich | Zendy; David C. Clarke | Zendy; Jeremy Grummet | Zendy; Justin S. Peters | Zendy; Anthony J. Costello | Zendy; Sam Norden | Zendy; Anthony J. Ryan | Zendy; Phillip Parente | Zendy; Christopher M. Hovens | Zendy; Niall M. Corcoran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy

Author(s) -

Marek Cmero,

Natalie J. Kurganovs,

Ryan Stuchbery,

Patrick J. McCoy,

Corrina Grima,

Anne Ngyuen,

Ken Chow,

Stefano Mangiola,

Geoff Macintyre,

Nicholas Howard,

Michael Kerger,

Philip Dundee,

Paul Ruljancich,

David C. Clarke,

Jeremy Grummet,

Justin S. Peters,

Anthony J. Costello,

Sam Norden,

Anthony J. Ryan,

Phillip Parente,

Christopher M. Hovens,

Niall M. Corcoran

Publication year - 2021

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.20.00337

Subject(s) - prostate cancer , androgen deprivation therapy , regulator , androgen receptor , bicalutamide , reprogramming , cancer research , medicine , epithelial–mesenchymal transition , oncology , downregulation and upregulation , androgen , cancer , biology , cell , metastasis , gene , genetics , hormone

Androgen receptor (AR) signaling is important in prostate cancer progression, and therapies that target this pathway have been the mainstay of treatment for advanced disease for over 70 years. Tumors eventually progress despite castration through a number of well-characterized mechanisms; however, little is known about what determines the magnitude of response to short-term pathway inhibition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research